<DOC>
	<DOCNO>NCT00359216</DOCNO>
	<brief_summary>This Phase 4 randomize , placebo-controlled , parallel-group , single-center , double-blind study evaluate effect mometasone furoate nasal spray ( MFNS ) subject Sleep-disordered Breathing ( SDB ) associate perennial allergic rhinitis ( PAR ) use Peak Nasal Inspiratory Flow ( PNIF ) , Embletta device home-monitored cardiopulmonary evaluation , rhinitis evaluation questionnaire . Approximately 30 subject 18 60 year age symptomatic PAR ( without SAR ) select randomized one study site . The anticipated duration subject participation study approximately 39 day . Subjects qualify Screening Visit complete 10-14 day run-in/screening period . Following run-in period , subject meet qualification Baseline Visit treat study medication 4 week .</brief_summary>
	<brief_title>The Effects Mometasone Furoate Nasal Spray Subjects With Sleep-disordered Breathing ( SDB ) Associated With Perennial Allergic Rhinitis ( Study P04726 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Demonstration willingness participate study comply procedure sign write informed consent . Ages 18 60 year , either sex , race . A 2year long history perennial allergic rhinitis ( PAR ) without SAR . Skin test positive relevant prevalent perennial allergen seasonal allergen subject also SAR do either Screening Visit within previous 12 month . At Screening Visit ( Visit 1 ) subject must TNSS &gt; =12 possible 24 , nasal congestion score 4 possible 6 congestion , Interference With Sleep average score ( 2 ) moderate 7 night prior Screening Visit . At Baseline Visit ( Visit 2 ) score , reflective previous 12 hour , 4 nasal congestion use categorical wholenumber symptom severity scale encompass 7 severity rating least 6 15 recording Runin period may include morning Baseline Visit ( Visit 2 ) . At Baseline Visit ( Visit 2 ) subject must TNSS &gt; =12 possible 24 reflective past 12 hour least 6 15 recording Runin period , may include morning Baseline Visit . Current complaint sleep disturbance symptomatic PAR score least 2 Interference Sleep scale least 4 8 AM diary recording Runin period may include morning Visit 2 ( Baseline ) . The number AH event per hour record exceed 30 per hour . Freedom clinically significant disease ( PAR SAR ) would interfere study evaluation . Confirmation subject he/she practice adequate contraception : Female volunteer childbearing potential ( include woman less 1 year postmenopausal woman sexually active study ) must agree use medically accept method contraception surgically sterilize prior screen receive protocolspecified medication . Women postmenopausal &gt; 1 year ( ie , woman experience 12 consecutive month amenorrhea ) exempt use contraception study . Acceptable method contraception include condom ( male female ) without spermicidal agent , diaphragm cervical cap spermicidal agent , medically prescribe intrauterine device ( IUD ) , oral injectable hormonal contraceptive , surgical sterilization ( eg , hysterectomy tubal ligation ) . Understanding , ability adhere , dose visit schedule , agreement record symptom severity score , medication time , concomitant medication , adverse event accurately consistently daily diary . Pregnant intention become pregnant study Breastfeeding intention breastfeed study within 30 day study completion Currently medication PAR , 10 day prior Screening Visit , treatment SAR PAR antihistamine nasal inhale corticosteroid . Current history frequent ( 2 episode per year past 2 year ) clinically significant sinusitis chronic purulent postnasal drip . Recent nasal septum ulcer , nasal surgery , nasal trauma ; postpone inclusion healing occur . A diagnosis rhinitis medicamentosa . Upper low respiratory tract sinus infection require antibiotic therapy last dose 14 day prior screen , viral upper low respiratory infection within 7 day prior screen . Nasal structural abnormality , include large nasal polyp mark septum deviation , significantly interfere nasal airflow . Bronchial asthma control shortacting beta 2agonist adrenergic receptor agonist . Current desensitization immunotherapy expectation receive increase dose study . Subject may receive desensitization treatment within 24 hour prior study visit . Failure observe designate washout period prohibit medication outline section 6.2 protocol . Previous randomization study . Current evidence clinically significant hematopoietic , cardiovascular , hepatic , immunologic , renal , neurologic , psychiatric , autoimmune disease , disease precludes subject 's participation study , subject 's ability complete diary card . Active quiescent tuberculosis infection respiratory tract , untreated fungal , bacterial , systemic viral infection , ocular herpes simplex . Compromised ability provide inform consent . A history noncompliance medication treatment protocol . Morbidly obese ( BMI &gt; = 40 ) . Nightshift work schedule standard asleep night/awake day cycle . Any clinically significant deviation appropriate reference range physical examination , investigator 's judgment , may interfere study evaluation affect subject safety . situation condition , opinion investigator , may interfere optimal participation study . Participation clinical study ( y ) . Subject staff , affiliate , family member staff personnel directly involve study . Subject allergic sensitivity study drug excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hypopnea Syndrome</keyword>
</DOC>